Remidio Invests in UK-Based Occuity to Advance AI-Powered Ophthalmic & Systemic Disease Screening

The partnership will focus on integrating technologies to develop a comprehensive myopia screening solution, addressing the increasing prevalence of myopia in India.

Bengaluru-based Remidio, a global leader in AI-driven ophthalmic solutions, has invested in UK-based Occuity, a handheld, optical screening and monitoring device developer.

This strategic investment strengthens Remidio’s position in non-invasive disease screening, complementing its expertise in AI-powered ophthalmic diagnostics and expanding its efforts to combat India’s growing myopia epidemic.

The partnership will focus on integrating technologies to develop a comprehensive myopia screening solution, addressing the increasing prevalence of myopia in India.

By 2050, nearly 48% of urban children are expected to be affected, with 20% experiencing rapid progression and around 4% facing severe complications that could lead to permanent vision loss.

A key innovation from this collaboration is India’s first handheld, non-invasive axial length measurement device for the detection and monitoring of myopia.

This device eliminates the need for expensive and complex eye exams, making early diagnosis more accessible, particularly for children.

Expanding Non-Contact Screening for Glaucoma & Vision Care

With fewer than 20,000 primary eye care practitioners across India, access to timely vision screening remains a major challenge, particularly in rural areas.

To address this gap, the partnership will also introduce a non-contact, handheld device capable of accurately assessing corneal thickness—a crucial parameter for managing glaucoma patients and evaluating suitability for laser eye procedures like LASIK.

By leveraging Remidio’s experience in AI-integrated diagnostics and scalable manufacturing, the collaboration aims to accelerate the global rollout of Occuity’s non-contact handheld screening solutions.

“We believe that non-invasive diagnostics are the future of healthcare, especially for large-scale public health challenges like diabetes and myopia,” said Dr Anand Sivaraman, CEO of Remidio.

“Occuity’s technology aligns perfectly with our mission to democratize high-quality screening and management, making preventive healthcare more accessible than ever before.”

Advancing Non-invasive Diabetes Detection Through Optical Technology

Beyond ophthalmology, the collaboration extends to systemic disease detection, particularly diabetes screening.

Occuity’s Indigo is an optical glucose meter that measures glucose levels through a simple eye scan, eliminating the need for finger-prick blood tests.

This innovation could significantly benefit India’s over 100 million diabetes patients by providing a painless, non-invasive alternative to regular glucose monitoring.

Dr Dan Daly, CEO and co-founder of Occuity emphasized the significance of this partnership, stating, “Remidio’s deep expertise in designing, developing, and manufacturing AI-integrated ophthalmic devices, along with their strong presence in the global ophthalmology market, makes them an ideal partner to expand the reach of our breakthrough non-contact screening devices. Their investment reflects our shared vision of transforming early disease detection and improving patient outcomes worldwide.”

Stay tuned for more such updates on Digital Health News.